Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Abbisko Cayman's Days Inventory or its related term are showing as below:
HKSE:02256's Days Inventory is not ranked *
in the Biotechnology industry.
Industry Median: 181.695 * Ranked among companies with meaningful Days Inventory only.
Abbisko Cayman's Days Inventory
stayed the same
from Dec. 2024 (0.00) to Dec. 2025 (0.00).
Inventory Turnover measures how fast the company turns over its inventory within a year.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abbisko Cayman (HKSE:02256) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Abbisko Cayman's Inventory Turnover for the
six
months ended in Dec. 2025 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Abbisko Cayman's Inventory to Revenue for the
six
months ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Abbisko Cayman Days Inventory Related Terms
Abbisko Cayman Days Inventory Historical Data
* Premium members only.
The historical data trend for Abbisko Cayman's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02256 vs VRTX, REGN, RVMD: Days Inventory Comparison
For the Biotechnology subindustry, Abbisko Cayman's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Abbisko Cayman Days Inventory vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Abbisko Cayman's Days Inventory distribution charts can be found below:
* The bar in red indicates where Abbisko Cayman's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Abbisko Cayman (HKSE:02256) has a Days Inventory of 0.00 as of Dec. 2025. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abbisko Cayman and its competitors. According to the industry distribution chart, Abbisko Cayman ranks #999999 out of 638 companies in the Biotechnology industry.
Is Abbisko Cayman's Days Inventory too high?
Abbisko Cayman's current Days Inventory is 0.00. Based on the distribution chart, Abbisko Cayman ranks #999999 out of 638 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Abbisko Cayman has a GF Score™ of 56/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Abbisko Cayman's Days Inventory compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Abbisko Cayman ranks #999999 out of 638 companies for Days Inventory. This places Abbisko Cayman in the lower half of its industry. The industry median Days Inventory is 181.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Biotechnology company?
The median Days Inventory among Biotechnology companies is 181.70, based on 638 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Abbisko Cayman and its competitors. For the Biotechnology industry, the median Days Inventory is 181.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Abbisko Cayman's current Days Inventory is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Abbisko Cayman stock overvalued right now?
Based on GuruFocus' analysis, Abbisko Cayman (HKSE:02256) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$12.30, compared to a current price of HK$10.54 — trading 14.3% below its estimated fair value. The current Days Inventory is 0.00. Abbisko Cayman's overall GF Score™ is 56/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Abbisko Cayman (HKSE:02256), the current Days Inventory is 0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Abbisko Cayman (HKSE:02256) Overvalued in 2026?
Based on GuruFocus' analysis, Abbisko Cayman stock appears to be undervalued.
The current stock price of HK$10.54 is trading 14.3% below its estimated GF Value™ of HK$12.30.
GuruFocus considers Abbisko Cayman to be Modestly Undervalued.
Key valuation signals for HKSE:02256:
Days Inventory: 0.00
GF Value™: HK$12.30 vs. price of HK$10.54 (14.3% below fair value)
No single metric tells the full story. See the HKSE:02256 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Abbisko Cayman Ltd is an investment holding company that operates through its subsidiaries which is a clinical-stage biopharmaceutical company dedicated to the discovery and development of medicines and differentiated small molecule oncology therapies. The company has pipeline of 21 program candidates, with a primary focus on oncology and pimicotinib has received approval from the China NMPA, and several other candidates are currently in clinical development stage. The company has only one business segment which is the development of medicines. Geographically, the company has it's concentration in European Union and Chinese mainland region.
56GF Score
Get the complete analysis for HKSE:02256
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02256 has been successfully added to your 
